George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVersarien Regulatory News (VRS)

Share Price Information for Versarien (VRS)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.1075
Bid: 0.105
Ask: 0.11
Change: 0.00125 (1.18%)
Spread: 0.005 (4.762%)
Open: 0.10625
High: 0.00
Low: 0.00
Prev. Close: 0.10625
VRS Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Sale of Korean Assets and Licencing of IP

11 Mar 2024 07:00

RNS Number : 2327G
Versarien PLC
11 March 2024
 

11 March 2024

Versarien Plc

("Versarien", the "Company" or the "Group")

Sale of Korean Assets and Licencing of IP

Versarien Plc (AIM: VRS), the advanced materials engineering group, announces that the Company has, in line with its stated strategy, entered into an agreement (the "Agreement") with MCK Tech Co. Ltd ("MCK Tech") to sell the Group's plant and equipment in South Korea ("Korean Plant") for a total consideration of £604,000, as described below, together with an exclusive licence agreement with MCK Tech for the use of five patents, owned by the Group (the "IP"), for additional fees as detailed below (together the "Transaction").

The Company continues to pursue its stated turnaround strategy. An integral part of this strategy is to dispose of non-core businesses and assets. The plant and equipment acquired from Hanwha Aerospace in South Korea in 2020 were identified as non-core and marketed for sale, the Transaction concludes this part of the Group asset sale process. The Group's mature businesses, AAC Cyroma Limited and Total Carbide Limited, continue to be marketed for sale and the Company is progressing discussions with a number of interested parties, though the timing of any further asset sales and the quantum of the funds that may be received remains uncertain.

The net proceeds of the Transaction will be used for the Group's corporate and working capital purposes. The Company continues to actively seek additional short and longer term funding solutions to support its turnaround strategy.

Further Details on the Transaction

Korean Plant

Under the Agreement MCK Tech is paying £604,000 for the Korean Plant, which comprises the assets of the CVD (Chemical Vapour Deposition) graphene business carried out by Versarien's subsidiary, Versarien Korea Limited, and owned by the Company. £60,400 has been paid and the remaining £543,600 will be paid in full by 31 July 2024 through the following instalments: £120,800 60 days from the date of the Agreement; £120,800 120 days from the date of the Agreement; and £302,000 payable on 31 July 2024. 

As at 31 March 2023, the date of Versarien's last notified balance sheet, the gross asset value of the Korean Plant was £844,151. Versarien Korea Limited, which operated the Korean Plant, made a loss after tax of £771,690 in the 18 months to 30 September 2022.

IP

In line with the Company's strategy to monetise intellectual property through licensing, Versarien has granted an exclusive licence to MCK Tech (the "Licence"), for an initial period of five years, to use five patents owned by the Company in their business in Korea. These five patent licences are in addition to 14 patents the Company licences to Graphene Lab Co Ltd. MCK Tech will pay Versarien an amount equal to 4.5% of the total sales revenue earned from products manufactured using the IP. If the sales revenue derived from the IP is less than £250,000 over the first two years of the Licence, the Licence will terminate and MCK Tech will pay Versarien £40,000 for use of the IP.

Dr Stephen Hodge, CEO of Versarien, commented: "As previously outlined, Versarien's strategy is to be a manufacturing-light business in the UK and licence our patents, know-how and other intellectual property to key partners. In line with this strategy we are pleased that we have secured the sale of the Korean CVD graphene production equipment and licenced five patents to MCK Tech. MCK Tech is a well-respected company that has developed graphene-based sensors for healthcare. MCK's CEO, Dr Seungmin Cho, is one of the pioneers of CVD graphene in Korea, formerly working as Group Leader at Samsung Techwin and Hanwha Aerospace, prior to founding MCK Tech in 2017, a joint venture with the Centre for Advanced Meta-Materials (CAMM) in Daejeon. We look forward to maintaining access to CVD graphene materials and supporting MCK Tech through collaborative efforts."

Dr Seungmin Cho, CEO of MCK Tech, commented: "Acquiring the CVD graphene production equipment is a strategic move to vertically integrate CVD graphene manufacturing and developing applications. Securing the assets and licensing the IP will help us to become a more dependable materials supplier for our valued customers and enable us to shorten the application development cycle to provide new CVD graphene applications covering the IT, military, and healthcare industries. As we are acquiring the heritage of Samsung Techwin and Hanwha Aerospace, we are building on their pioneering work to consolidate our position in the graphene industry.  Most of all, MCK Tech is pleased to establish a firm relationship with Versarien, a renowned graphene company, and is looking forward to collaborating in commercialising CVD graphene as well as graphene flakes in the years to come."

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the Company's obligations under Article 17 of MAR.

For further information please contact:

 

Versarien

Stephen Hodge, Chief Executive Officer

Chris Leigh, Chief Financial Officer

 

c/o IFC

SP Angel Corporate Finance (Nominated Adviser and Broker)

Matthew Johnson, Adam Cowl

 

+44 (0)20 3470 0470

 

IFC Advisory Limited (Financial PR and Investor Relations)

Tim Metcalfe, Zach Cohen

+44 (0) 20 3934 6630

 

For further information please see: http://www.versarien.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DISFLFFDVEITIIS
Date   Source Headline
28th Mar 20247:00 amRNSAudited Results for year ended 30 September 2023
28th Mar 20247:00 amRNSTotal Voting Rights
20th Mar 20248:33 amRNSPlacing to raise £615,000
14th Mar 20247:00 amRNSSouth American Graphinks Agreements
11th Mar 20247:00 amRNSSale of Korean Assets and Licencing of IP
16th Feb 20242:22 pmRNSNotification of final results
7th Feb 20247:00 amRNSReceipt of Legal Claims
31st Jan 20247:00 amRNSTotal Voting Rights
23rd Jan 20244:53 pmRNSHolding(s) in Company
23rd Jan 20241:24 pmRNSHolding(s) in Company
19th Jan 20247:00 amRNSPlacing to raise £400,000
10th Jan 202411:29 amRNSResult of General Meeting
20th Dec 20237:00 amRNSCompany Update and Notice of General Meeting
30th Nov 20237:00 amRNSTotal Voting Rights
8th Nov 20237:00 amRNSPlacing to raise £454,822
30th Oct 202311:52 amRNSResult of General Meeting
30th Oct 20237:00 amRNSGeneral Meeting Statement
12th Oct 20237:00 amRNSNotice of General Meeting
2nd Oct 20237:00 amRNSCorporate Update
13th Sep 20237:00 amRNSTurnaround Strategy - Gnanomat Grant Award
31st Jul 20237:00 amRNSTotal Voting Rights
18th Jul 20234:31 pmRNSDirectorate Changes
14th Jul 20237:00 amRNSPlacing to raise £650,000
4th Jul 202310:54 amRNSResult of General Meeting
4th Jul 20237:00 amRNSGeneral Meeting Statement
15th Jun 20237:00 amRNSNotice of General Meeting
9th Jun 20237:00 amRNSInterim Results
31st May 20237:00 amRNSTotal Voting Rights
17th May 20237:00 amRNSSuccessful Cementene precast concrete trials
3rd May 20239:30 amRNSPlacing and Update on Turnaround Strategy
31st Mar 20237:00 amRNSTotal Voting Rights
29th Mar 202311:22 amRNSResult of AGM
29th Mar 20237:00 amRNSAGM Statement
15th Mar 20237:00 amRNSPlacing to raise £318,000
14th Mar 20232:56 pmRNSFurther re Resignation of Chief Executive Officer
10th Mar 20237:00 amRNSResignation of Chief Executive Officer
6th Mar 20237:00 amRNSCostain Civil Engineering Project
1st Mar 202312:00 pmRNSUmbro Launch
28th Feb 20237:00 amRNSNotice of AGM and Posting of Annual Report
21st Feb 20237:00 amRNSResults for the 18 months ended 30 September 2022
9th Feb 20238:33 amRNSAIM Rule 17 Update
27th Jan 20237:00 amRNSGraphene-Wear OEKO-TEX Eco Passport certification
24th Jan 20231:56 pmRNSFinal Results Update
30th Dec 20227:00 amRNSTotal Voting Rights
6th Dec 20229:40 amRNSPlacing to raise £1.85 million
5th Dec 20224:40 pmRNSSecond Price Monitoring Extn
5th Dec 20224:35 pmRNSPrice Monitoring Extension
5th Dec 20227:00 amRNSG-SCALE Update & Innovate UK Loan Variation
2nd Dec 20224:35 pmRNSPrice Monitoring Extension
1st Dec 20224:41 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.